GTBP GT Biopharma, Inc.
GT Biopharma, Inc. (GTBP) is expected to report earnings on February 15, 2027, before the market open. The stock has had a Post-Earnings Announcement Drift (PEAD) of -21.3% since its last earnings release on November 16, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About GT Biopharma, Inc.
GT Biopharma Inc. is an immuno-oncology company. It discovers, develops and commercializes drugs of therapeutic molecules for the treatment of cancer, myeloma, osteolytic lesions and other unmet medical needs. GT Biopharma Inc., formerly known as OXIS International Inc., is based in Tampa, Florida.
Sector
Healthcare
Industry
Biotechnology
Charts powered in part by Lightweight Charts™ by TradingView.